Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.

about

Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.

Item

http://www.wikidata.org/entity/Q38737411

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Effects of toceranib phosphate ...... ug resistant lymphoma in dogs.

@en

type

Item

label

Effects of toceranib phosphate ...... ug resistant lymphoma in dogs.

@en

prefLabel

Effects of toceranib phosphate ...... ug resistant lymphoma in dogs.

@en

P1476

Effects of toceranib phosphate ...... ug resistant lymphoma in dogs.

@en

P2093

Asuka Setoguchi

http://www.w3.org/2001/XMLSchema#string

Hajime Tsujimoto

http://www.w3.org/2001/XMLSchema#string

Hiroki Yamazaki

http://www.w3.org/2001/XMLSchema#string

Masashi Takahashi

http://www.w3.org/2001/XMLSchema#string

Momoi Yasuyuki

http://www.w3.org/2001/XMLSchema#string

Munekazu Nakaichi

http://www.w3.org/2001/XMLSchema#string

Naoki Miura

http://www.w3.org/2001/XMLSchema#string

Yasuyuki Endo

http://www.w3.org/2001/XMLSchema#string

Yu-Chang Lai

http://www.w3.org/2001/XMLSchema#string

Yuko Goto-Koshino

http://www.w3.org/2001/XMLSchema#string

P2860

Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.

Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.

Canine lymphoma: a review.

The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer.

Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma.

Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.

Evaluation of tyrosine-kinase receptor c-kit mutations, mRNA and protein expression in canine lymphoma: might c-kit represent a therapeutic target?

Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document.

P304

1225-1229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1292/JVMS.16-0457

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28592719

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

5559368

http://www.w3.org/2001/XMLSchema#string